Background: Vitiligo is the most prevalent pigmentary disorder which occurs worldwide, with an incidence rate\r\nbetween 0.1-4 percent. It is anticipated that the discovery of biological pathways of vitiligo pathogenesis will\r\nprovide novel therapeutic and prophylactic targets for future approaches to the treatment and prevention of\r\nvitiligo. The purposes of this study were evaluating the efficacy of supplemental zinc on the treatment of vitiligo.\r\nMethods: This randomized clinical trial was conducted for a period of one year. Thirty five patients among 86\r\nparticipants were eligible to entrance to the study. The patients in two equal randomized groups took topical\r\ncorticosteroid and combination of oral zinc sulfate-topical corticosteroid.\r\nResults: The mean of responses in the corticosteroid group and the zinc sulfate-corticosteroid combination group\r\nwere 21.43% and 24.7%, respectively.\r\nConclusion: Although, the response to corticosteroid plus zinc sulfate was more than corticosteroid, there was no\r\nstatistically significant difference between them. It appeared that more robust long-term randomized controlled\r\ntrials on more patients, maybe with higher doses of zinc sulfate, are needed to fully establish the efficacy of oral\r\nzinc in management of vitiligo.
Loading....